热门资讯> 正文
Viatris完成Aculys Pharma收购
2025-10-16 05:19
- Viatris (NASDAQ:VTRS) has completed its acquisition of Aculys Pharma, and with it, the commercialization and development rights for Japan for pitolisant for excessive daytime sleepiness.
- The company is planning a submission for marketing approval to Japanese regulators for the selective/inverse agonist of the histamine H3 receptor by the end of the year.
- Viatris also gains Spydia (diazepam) nasal spray, approved in Japan in June 2025 for epileptic seizures.
- Aculys also has several candidates in phase 3 development for other central nervous system conditions.
More on Viatris
- Viatris: Indore Plant Could Boost 2026 Numbers
- Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
- Covering The Flaws In The Viatris Undervaluation Argument
- Viatris shares break six-session winning streak
- FDA introduces program to expedite review of domestic generic drugs
推荐文章
美股机会日报 | “大空头”出手！重仓做空英伟达及Palantir；特斯拉大股东拒绝万亿美元薪酬方案
华盛早报 | 亚马逊加入OpenAI“朋友圈”，股价大涨4%创新高！分析师唱多英伟达市值上8.5万亿美元
美股机会日报 | 大摩警告！若薪酬方案被否，特斯拉或跌超10％；微软获批向阿联酋出口最新款英伟达芯片
美债上演大反攻 “Sell America”大错特错! 嘴上喊“美国例外论坍塌”的机构实际上狂买美债?
明略科技-W今日上市：香港公开发售获4452.86倍认购
新能源汽车“银十”热销 多家车企交付量破纪录
英伟达市值突破 5 万亿：回顾它与加密货币的曾经蜜月期
“股神”巴菲特旗下伯克希尔财报出炉，现金储备超3800亿美元创历史记录！速看前五大持仓
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
